Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. - Wikidata - awgldk - TriplyDB

Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis.

Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis.

http://www.wikidata.org/entity/Q46029821

about

Fluoroquinolones for treating tuberculosis (presumed drug-sensitive)Recent developments in treatment of latent tuberculosis infection Emerging strategies for the treatment of pulmonary tuberculosis: promise and limitations?Effects of Fluroquinolones in Newly Diagnosed, Sputum-Positive Tuberculosis Therapy: A Systematic Review and Network Meta-Analysis Quality of outcome reporting in phase II studies in pulmonary tuberculosis Current prospects for the fluoroquinolones as first-line tuberculosis therapy A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis Influence of M. tuberculosis lineage variability within a clinical trial for pulmonary tuberculosis Nine- to Twelve-Month Anti-Tuberculosis Treatment Is Associated with a Lower Recurrence Rate than 6-9-Month Treatment in Human Immunodeficiency Virus-Infected Patients: A Retrospective Population-Based Cohort Study in Taiwan The Effectiveness and Safety of Fluoroquinolone-Containing Regimen as a First-Line Treatment for Drug-Sensitive Pulmonary Tuberculosis: A Systematic Review and Meta-Analysis Pipeline of drugs for related diseases: tuberculosis Challenges in the clinical assessment of novel tuberculosis drugs.Recent advances in tuberculosis: New drugs and treatment regimens.Month 2 culture status and treatment duration as predictors of tuberculosis relapse risk in a meta-regression model.Predictors of delayed culture conversion among Ugandan patients.Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial.The association between symptoms and microbiologically defined response to tuberculosis treatment.Geographic differences in time to culture conversion in liquid media: Tuberculosis Trials Consortium study 28. Culture conversion is delayed in Africa.Verapamil, and its metabolite norverapamil, inhibit macrophage-induced, bacterial efflux pump-mediated tolerance to multiple anti-tubercular drugs.Antimycobacterial drugs modulate immunopathogenic matrix metalloproteinases in a cellular model of pulmonary tuberculosis.Importance of confirming data on the in vivo efficacy of novel antibacterial drug regimens against various strains of Mycobacterium tuberculosis Baseline predictors of sputum culture conversion in pulmonary tuberculosis: importance of cavities, smoking, time to detection and W-Beijing genotype Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations.Current approaches to tuberculosis in the United States.Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model Evaluation of time to detection of Mycobacterium tuberculosis in broth culture as a determinant for end points in treatment trials.High-dose rifapentine with moxifloxacin for pulmonary tuberculosis.Linezolid for treatment of chronic extensively drug-resistant tuberculosis.An evaluation of culture results during treatment for tuberculosis as surrogate endpoints for treatment failure and relapse.Comparative studies evaluating mouse models used for efficacy testing of experimental drugs against Mycobacterium tuberculosis.Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis Chest radiograph findings and time to culture conversion in patients with multidrug-resistant tuberculosis and HIV in Tugela Ferry, South Africa.Tuberculosis outcomes in Papua, Indonesia: the relationship with different body mass index characteristics between papuan and non-Papuan ethnic groups.A multi-arm multi-stage clinical trial design for binary outcomes with application to tuberculosis Development of new vaccines and drugs for TB: limitations and potential strategic errors An update on the use of rifapentine for tuberculosis therapy.Predictors of two months culture conversion in multidrug-resistant tuberculosis: findings from a retrospective cohort study Treatment of drug-resistant tuberculosis.The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications.Target product profile of a molecular drug-susceptibility test for use in microscopy centers.

P2860

Q24202081-31C957B3-F564-4281-9FDE-8E8BA7E93339 Q24630473-CF81CD73-6D60-4FAC-9482-9772D7B3FBB2 Q26771997-91BA77A8-6EF5-4724-9EE1-ACA4D1B3C61B Q26775757-55DDF9B0-29AA-4CC3-9197-6F547F8ECA61 Q26777160-215531C8-D339-447E-883A-DF15D03B9865 Q26823843-FE72B8AA-597D-4F0A-833B-E6BF4C03F1C1 Q27004482-25F92292-D708-47CE-85F7-37287693F232 Q28474010-22FB5554-5DE9-476E-A427-5DEB61A8BD64 Q28551297-F1848B51-A66D-4528-8DD6-EE2950CA001A Q28553119-43E0032A-A28D-492B-84CB-336E27F035F9 Q28818217-34DB11F2-373B-4DE9-9230-EF6E0015DF57 Q30251933-4852E70C-7F35-4F8A-A409-7A8D3C1DEE4B Q30360811-FDE3F2B5-589F-44D6-9002-1D17B7B5B24B Q31126318-B6B8799A-5A86-4A59-A4AE-584C06F8D8E6 Q33595569-0612A27D-255E-4F83-9077-A182F7C99A10 Q33735589-3460D60D-8010-49F3-B6C5-01809BC998BC Q33872018-15F973FE-9AB1-44BF-8224-C6909A8DB661 Q33873368-7D0F14D2-D2D8-4766-8DE9-DF485DFFCE0B Q33947806-670B6B47-4E1D-4C70-8674-CB4B3CE606FF Q34058316-10728267-E601-4A51-B0F6-28B1712579A4 Q34092117-996EC1D1-30A9-4DF8-BE2A-C382ED9B9D04 Q34125133-CF238A47-D95C-484F-8177-5C895505C138 Q34150929-056D95F1-D3F1-41D1-8ECB-FD0BB9167253 Q34279727-42623DC0-356A-4B67-84EF-F68110C16A6F Q34290003-4FD841DF-6379-4D95-8382-908B4CC6DD20 Q34433240-ACACC58D-AAF0-46EE-9864-B4615D54DF52 Q34519945-F89CE75B-4AFA-43CC-9434-E2A1A4DF4EF1 Q34644127-38DD246B-AEBB-4E2E-A5A7-C16BD1D03E95 Q34718431-9C45FCC6-4B84-4AF1-B5E0-39B76FD03FC8 Q34737143-0C0F255D-2A09-42B2-907E-F0A113E51946 Q34777926-EA978655-CC16-48D8-9E22-CD052F0AB94B Q34989566-4F8B149B-D9E4-4CC1-BEBA-3A1FA2D84ED6 Q35006182-7FCC7A4D-95FD-4283-9D0A-309FD0414411 Q35042658-85F67A5D-6E90-46DF-9AE2-B64C4EB14BC2 Q35065531-508D0006-9B14-401B-B6C5-18E25761A8A1 Q35084363-4F713C9D-7875-4462-B25F-C35CA3766537 Q35140245-2FBCF938-FC5A-4159-ADF0-ECD0C4C5FE2D Q35187176-98D12A25-7FC1-4F1A-B8E0-91FE89979C89 Q35191432-BB18C37C-F86F-43EA-A4EA-57F52738C581 Q35588123-AA6786AF-1EEA-4435-8C48-93D377364B85

P2860

Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis.

http://www.wikidata.org/entity/Q46029821

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh-hant

name

Substitution of moxifloxacin f ...... ent of pulmonary tuberculosis.

@en

Substitution of moxifloxacin f ...... ent of pulmonary tuberculosis.

@nl

type

label

Substitution of moxifloxacin f ...... ent of pulmonary tuberculosis.

@en

Substitution of moxifloxacin f ...... ent of pulmonary tuberculosis.

@nl

prefLabel

Substitution of moxifloxacin f ...... ent of pulmonary tuberculosis.

@en

Substitution of moxifloxacin f ...... ent of pulmonary tuberculosis.

@nl

P1433

Q46029821-9F752D9D-F1EB-4EF3-98F5-38FC8EC5677E

P1476

Q46029821-A59AC3D5-FBD5-42D5-B742-C64ECCB25A05

P2093

Q46029821-1D4E4516-0758-4DF0-A88C-18B814078139

Q46029821-1D6F3F7C-2F54-4698-A1CD-D6BCBDC861D2

Q46029821-395A1EDF-E6D6-452F-8496-416716996DF3

Q46029821-489EE54A-C3D2-4ED0-B18D-676F02961EA7

Q46029821-78E4BD05-971A-4826-934C-D75CA118224B

Q46029821-8D7A2DCE-AAD4-4B57-A8F6-C8CDA94D641E

Q46029821-A071F354-365F-4388-BDCA-19D9BAD10DE2

Q46029821-B56D46F9-D096-488F-BCB7-4A61FAE49914

Q46029821-BBB41B79-5C01-448B-A650-1BAE0C2950DD

Q46029821-C5C71EEB-5F71-4B33-9AC6-58BBFEA61222

P2860

Q46029821-0BF280E5-2EF9-4033-87CD-0AB2C7D9B4A7

Q46029821-0F3AF82C-6E4E-4FDD-8B0E-4F0C676E0FA9

Q46029821-175C905C-E950-4210-BC67-8D2F69EE28AB

Q46029821-20A3060A-C092-4EB0-A3F8-1193A178FAE7

Q46029821-2214DCFE-AA9A-46F6-AE49-A61744010E6A

Q46029821-370CB256-A017-4EE2-89A3-E9138C87FA27

Q46029821-3C93645C-0F30-49F1-AD4D-9606777658EE

Q46029821-42FAED13-7B96-4982-BEA3-89F0BFB02215

Q46029821-544CBC2F-8DD5-44BA-AF8E-9EAD50B68050

Q46029821-63A21E33-243B-4199-B680-F7EB9B5C6DDC

P304

Q46029821-D64429D3-B2F8-4997-8C35-B9BE5DB58426

P31

Q46029821-9D1C692C-A6D5-4E76-AB3A-C47B2EAC24F1

P356

Q46029821-C28D71AD-BD61-45E8-A71B-67DA3BAD3B22

P407

Q46029821-B92B62C5-E45F-4F72-91AB-407DA702B38C

P433

Q46029821-D8EBC20B-E207-4464-880F-A4A765B32B6D

P478

Q46029821-FC334E0B-878E-4BA9-817E-86D6167D672D

P50

Q46029821-12C831F1-531C-4140-9533-FF5BD2D9FD60

Q46029821-57C95F30-E53F-47FD-AA0B-4C99A695154B

Q46029821-8FF739AF-4957-491A-947D-39CC89B0189B

Q46029821-CA20AE4E-EFBC-4F15-9966-8DB23C12116C

Q46029821-CFC07F3F-7EFF-4981-BF92-894E87449DDE

P577

Q46029821-3B4E96EA-AFC3-4E78-9943-D9F290832104

P698

Q46029821-BD223F59-079F-43A4-B8C6-12395AB8E217

P921

Q46029821-EBC6318A-891B-49C4-9149-1BAA952D67B1

P356

RCCM.200901-0078OC

P1433

American Journal of Respiratory and Critical Care Medicine

P1476

Substitution of moxifloxacin f ...... ent of pulmonary tuberculosis.

@en

P2093

Andrew Vernon

http://www.w3.org/2001/XMLSchema#string

Elizabeth Guy

http://www.w3.org/2001/XMLSchema#string

Eric L Nuermberger

http://www.w3.org/2001/XMLSchema#string

Gina Maltas

http://www.w3.org/2001/XMLSchema#string

Grace Muzanye

http://www.w3.org/2001/XMLSchema#string

Jacques H Grosset

http://www.w3.org/2001/XMLSchema#string

John L Johnson

http://www.w3.org/2001/XMLSchema#string

Lorna Bozeman

http://www.w3.org/2001/XMLSchema#string

Margarita Villarino

http://www.w3.org/2001/XMLSchema#string

Maria Corazon Leus

http://www.w3.org/2001/XMLSchema#string

P2860

Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model

Outpatient gatifloxacin therapy and dysglycemia in older adults

Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice

Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis

Powerful bactericidal activity of sparfloxacin (AT-4140) against Mycobacterium tuberculosis in mice

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America

Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies.

Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers.

The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis.

Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis.

P304

273-280

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1164/RCCM.200901-0078OC

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

180

http://www.w3.org/2001/XMLSchema#string

P50

Charles M. Heilig

Nesri Padayatchi

Richard E Chaisson

P577

2009-04-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19406981

http://www.w3.org/2001/XMLSchema#string

P921

Akafuba bulwadde